President Trump’s December 2025 executive order directed expedited DEA action to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026 the Department of Justice immediately rescheduled FDA-approved products and state-licensed medical marijuana into Schedule III while launching a new expedited administrative hearing on broader rescheduling. That hearing ran from June 29 through July 15, 2026, at DEA headquarters and is now complete. A final rulemaking decision remains pending and could occur any time in the coming months, subject to standard procedural timelines and possible legal challenges. These steps have accelerated the process relative to the stalled 2024 proposal and explain current trader focus on late-2026 resolution windows.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено$791,846 Обс.
September 30
14%
December 31
31%
$791,846 Обс.
September 30
14%
December 31
31%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Ринок відкрито: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...President Trump’s December 2025 executive order directed expedited DEA action to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026 the Department of Justice immediately rescheduled FDA-approved products and state-licensed medical marijuana into Schedule III while launching a new expedited administrative hearing on broader rescheduling. That hearing ran from June 29 through July 15, 2026, at DEA headquarters and is now complete. A final rulemaking decision remains pending and could occur any time in the coming months, subject to standard procedural timelines and possible legal challenges. These steps have accelerated the process relative to the stalled 2024 proposal and explain current trader focus on late-2026 resolution windows.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено



Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання